Cytogen deal

OncoScint sales fell to $259,000 in the fourth quarter ended Jan. 2 from $503,000 in the third quarter ended Oct. 2, 1993. Total 1993 sales were $1.6 million.

The Princeton, N.J., company also said that its CytoRad business unit, established to fund the development of certain nuclear oncology products, is considering changing the companies' relationship. ...